-
Mashup Score: 0Cabozantinib Plus Atezolizumab Improves PFS in mCRPC - 8 month(s) ago
Home > mCRPC > Cabozantinib Plus Atezolizumab Improves PFS in mCRPC Newly released results from the phase 3 CONTACT-02 trial demonstrated the effectiveness of cabozantinib plus atezolizumab by meeting one of the trial’s primary end points—progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC)— showing a significant improvement at primary analysis. “Patients with [mCRPC] face a poor prognosis of less than 2 years, and many who progress on a novel hormonal
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Atezolizumab With or Without Radiotherapy for Advanced Penile Cancer - 9 month(s) ago
Advanced penile squamous cell carcinoma is a rare disease with a 21% 2-year overall survival (OS) rate. The study’s primary end point was 1-year progression-free survival (PFS) for the full cohort, which was reached if the actual 1-year PFS was at least 35%. Secondary end points included OS, objective response rate (ORR), and tolerability. A total of 31 patients with advanced penile cancer were included in the study. Each patient received atezolizumab 1200 mg once every 3 weeks, and 20 patients received
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet-
While the primary end point of a study investigating #atezolizumab with radiotherapy for advanced penile cancer was not met, antitumor activity from atezolizumab was seen in a subset of patients. Learn more: https://t.co/vo24zLs6Ms https://t.co/e0jUR1uUiX
-
-
Mashup Score: 1Advances and Challenges in Pediatric Alveolar Soft Part Sarcoma - 10 month(s) ago
Jeffrey Dome, MD, PhD, discusses how the use of atezolizumab has impacted the treatment of pediatric patients with alveolar soft part sarcoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Jeffrey Dome, MD, PhD, discusses how #atezolizumab has impacted the treatment of pediatric patients with alveolar soft part #sarcoma. | @childrenshealth https://t.co/9MuCWWET9d
-
-
Mashup Score: 0Please wait whilst we redirect you - 10 month(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
🔥🚨Hot off the press @TheLancet #IPSOS phase 3 trial of 1st line #Atezolizumab monotherapy vs single-agent #chemotherapy in pts with advanced #NSCLC ineligible for a platinum-containing chemo. Study showed better #OS & #Quality of life with Atezo. 👇🏼 https://t.co/0CCrBtCRZM https://t.co/07cNRS3SVP
-
-
Mashup Score: 0
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC progressing after initial ICI therapy.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Elizabeth Plimack @ERPlimackMD provides an overview of a recent phase 2 trial of #guadecitabine plus #atezolizumab in metastatic urothelial carcinoma progressing after initial immune checkpoint inhibitor therapy in our latest interview. Watch now: https://t.co/ILi8rZ0vyU https://t.co/rvXDpJUGpy
-
-
Mashup Score: 0
According to Alice P. Chen, MD, the phase 2 study of atezolizumab alone or atezolizumab plus bevacizumab has a unique design.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At @theNCI, #atezolizumab alone or in combination with #bevacizumab is being investigated for the treatment of patients with alveolar soft part #sarcoma. https://t.co/eYid3iCJDE
-
-
Mashup Score: 1Atezolizumab Added to SOC in HER2-Positive Breast Cancer Does Not Increase Responses - 1 year(s) ago
Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The addition of #atezolizumab to neoadjuvant dose-dense doxorubicin and cyclophosphamide–paclitaxel with standard of care #pertuzumab and trastuzumab did not increase pCR in high-risk patients with HER2-positive early breast cancer vs placebo. #bcsm https://t.co/zZVXE9mouy
-
-
Mashup Score: 2
At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Improved immunogenicity with neoadjuvant #atezolizumab seen was in patients with locally advanced cervical cancer, according to results from the NRG-GY017 trial. #gyncsm #SGO2023 #SGOMtg https://t.co/EGRbqsVaTk https://t.co/h7fEjNC1yY
-
-
Mashup Score: 0Atezolizumab Plus Chemotherapy Shows Potential for Improved OS in Urothelial Carcinoma - 1 year(s) ago
Final overall survival data from two arms of the phase 3 IMvigor130 trial display the potential for atezolizumab in addition to chemotherapy for patients with urothelial carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
First-line #atezolizumab + platinum-based chemo + gemcitabine trended toward improved OS in patients with locally advanced or metastatic urothelial carcinoma. #blcsm #GU23 | @MDAndersonNews @drenriquegrande https://t.co/5wMMKOi9fe
-
-
Mashup Score: 0Atezolizumab safe before, during chemoradiation, active in women with cervical cancer - 1 year(s) ago
Atezolizumab administered before and during chemoradiation appeared safe and demonstrated immune-modulating activity among women with node-positive locally advanced cervical cancer, according to study results. Researchers presented the study findings in a plenary session during the Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CervicalCancerAwarenessMonth Atezolizumab administered before and during chemoradiation appeared safe and demonstrated immune-modulating activity. https://t.co/nPu4LdfILk #Tecentriq @genentech #womenshealth #Atezolizumab #CervicalCancer #Cancer #HemOnc #OncAlert #MedEd
-
Newly released results from the phase 3 CONTACT-02 trial demonstrated the effectiveness of #cabozantinib plus #atezolizumab for #mCRPC by meeting one of the trial’s primary end points: https://t.co/ewwINmsJ8K https://t.co/v146JemD81